JPS6089422A - 抗骨粗鬆症剤 - Google Patents
抗骨粗鬆症剤Info
- Publication number
- JPS6089422A JPS6089422A JP58198454A JP19845483A JPS6089422A JP S6089422 A JPS6089422 A JP S6089422A JP 58198454 A JP58198454 A JP 58198454A JP 19845483 A JP19845483 A JP 19845483A JP S6089422 A JPS6089422 A JP S6089422A
- Authority
- JP
- Japan
- Prior art keywords
- osteoporosis
- cause
- bone
- group
- dihydroxycholecalciferol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001132 Osteoporosis Diseases 0.000 title abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 5
- 230000005856 abnormality Effects 0.000 abstract description 4
- 208000005368 osteomalacia Diseases 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 208000037147 Hypercalcaemia Diseases 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 230000000148 hypercalcaemia Effects 0.000 abstract description 2
- 208000030915 hypercalcemia disease Diseases 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 210000001685 thyroid gland Anatomy 0.000 abstract description 2
- FCKJYANJHNLEEP-SRLFHJKTSA-N 24,25-dihydroxycholecalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-SRLFHJKTSA-N 0.000 abstract 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 abstract 2
- FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract 1
- 235000005282 vitamin D3 Nutrition 0.000 abstract 1
- 239000011647 vitamin D3 Substances 0.000 abstract 1
- 229940021056 vitamin d3 Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 241001553178 Arachis glabrata Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001225 polyester resin Polymers 0.000 description 1
- 239000004645 polyester resin Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58198454A JPS6089422A (ja) | 1983-10-24 | 1983-10-24 | 抗骨粗鬆症剤 |
| US06/662,044 US4590184A (en) | 1983-10-24 | 1984-10-18 | Antiosteoporotic pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient |
| DE19843438821 DE3438821A1 (de) | 1983-10-24 | 1984-10-23 | Verwendung von 24,25-dihydroxycholecalciferol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58198454A JPS6089422A (ja) | 1983-10-24 | 1983-10-24 | 抗骨粗鬆症剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6089422A true JPS6089422A (ja) | 1985-05-20 |
| JPH0132208B2 JPH0132208B2 (en, 2012) | 1989-06-29 |
Family
ID=16391371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58198454A Granted JPS6089422A (ja) | 1983-10-24 | 1983-10-24 | 抗骨粗鬆症剤 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4590184A (en, 2012) |
| JP (1) | JPS6089422A (en, 2012) |
| DE (1) | DE3438821A1 (en, 2012) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61109721A (ja) * | 1984-11-01 | 1986-05-28 | Kureha Chem Ind Co Ltd | 骨粗しよう症における疼痛軽減剤 |
| JPS63166830A (ja) * | 1986-12-29 | 1988-07-11 | Kureha Chem Ind Co Ltd | 老化防止剤 |
| JPS63166829A (ja) * | 1986-12-29 | 1988-07-11 | Kureha Chem Ind Co Ltd | 骨強度増強剤 |
| JPS63310828A (ja) * | 1987-06-10 | 1988-12-19 | Kureha Chem Ind Co Ltd | 経口骨折治癒促進剤 |
| JPH02231425A (ja) * | 1988-03-23 | 1990-09-13 | Teva Pharmaceut Ind Ltd | ヒトにおけるオステオポローシスの治療方法及び治療用組成物 |
| KR950000153A (ko) * | 1993-06-21 | 1995-01-03 | 아라끼 타다시 | 신성골이영양증(Renal Osteodystrophy)의 골질량감소 억제제 |
| US6263752B1 (en) | 1998-01-07 | 2001-07-24 | Nsk Ltd. | Transmission for automobiles and bearing therefor |
| US7674481B2 (en) * | 2003-04-09 | 2010-03-09 | Osmose, Inc. | Micronized wood preservative formulations |
| US8722198B2 (en) | 2004-05-17 | 2014-05-13 | Osmose, Inc. | Method of preserving wood by injecting particulate wood preservative slurry |
| US8871277B2 (en) | 2003-06-17 | 2014-10-28 | Osmose, Inc. | Particulate wood preservative and method for producing the same |
| US9775350B2 (en) | 2004-10-14 | 2017-10-03 | Koppers Performance Chemicals Inc. | Micronized wood preservative formulations in organic carriers |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL74617A (en) * | 1985-03-15 | 1988-11-15 | Yeda Res & Dev | Compositions comprising a vitamin d derivative and method for the local treatment of bone fractures in animals |
| JPS6391323A (ja) * | 1986-10-03 | 1988-04-22 | Kureha Chem Ind Co Ltd | 抗尿路結石症剤 |
| US5001118A (en) * | 1986-12-29 | 1991-03-19 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for preventing senescence and increasing bone mass |
| US4997824A (en) * | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
| JP2856444B2 (ja) * | 1989-07-28 | 1999-02-10 | 呉羽化学工業株式会社 | ビタミンｄ▲下３▼代謝産物製剤 |
| US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
| JPH04129306U (ja) * | 1991-05-22 | 1992-11-26 | 三菱自動車工業株式会社 | サスペンシヨンアームの支持構造 |
| JPH04130507U (ja) * | 1991-05-27 | 1992-11-30 | 三菱自動車工業株式会社 | トルクロツドの取付構造 |
| KR960013798B1 (ko) * | 1992-04-24 | 1996-10-10 | 재단법인 한국전자통신연구소 | 평면 도파로형 공간 스위치 |
| AU666529B2 (en) * | 1992-04-24 | 1996-02-15 | Wisconsin Alumni Research Foundation | Method of treating osteoporosis with 1 alpha, 24 (R)-dihydroxy-22 (E)-dehydro-vitamin D3 |
| US5354743A (en) * | 1992-09-15 | 1994-10-11 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome with vitamin D |
| JP2684587B2 (ja) * | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
| US5552392A (en) * | 1993-11-03 | 1996-09-03 | Wisconsin Alumni Research Foundation | Method of treating hypoparathyroidism with (20S) vitamin D compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55136229A (en) * | 1979-04-10 | 1980-10-23 | Teijin Ltd | Adjustment of bone metabolism in warm-blooded animal and drug for it |
| JPS55139320A (en) * | 1979-04-16 | 1980-10-31 | Teijin Ltd | Bone metabolism regulator |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3715374A (en) * | 1972-05-05 | 1973-02-06 | Wisconsin Alumni Res Found | 24,25-dihydroxycholecalciferol |
| US4338250A (en) * | 1981-04-27 | 1982-07-06 | Wisconsin Alumni Research Foundation | 1-Hydroxylation process |
| US4456553A (en) * | 1982-05-07 | 1984-06-26 | Teijin Limited | Vitamin D3 derivatives, process for preparation thereof, and antigens comprising said derivatives to be used for preparation of antibodies for immunochemical assay and antibodies prepared therefrom |
-
1983
- 1983-10-24 JP JP58198454A patent/JPS6089422A/ja active Granted
-
1984
- 1984-10-18 US US06/662,044 patent/US4590184A/en not_active Expired - Lifetime
- 1984-10-23 DE DE19843438821 patent/DE3438821A1/de active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55136229A (en) * | 1979-04-10 | 1980-10-23 | Teijin Ltd | Adjustment of bone metabolism in warm-blooded animal and drug for it |
| JPS55139320A (en) * | 1979-04-16 | 1980-10-31 | Teijin Ltd | Bone metabolism regulator |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61109721A (ja) * | 1984-11-01 | 1986-05-28 | Kureha Chem Ind Co Ltd | 骨粗しよう症における疼痛軽減剤 |
| JPS63166830A (ja) * | 1986-12-29 | 1988-07-11 | Kureha Chem Ind Co Ltd | 老化防止剤 |
| JPS63166829A (ja) * | 1986-12-29 | 1988-07-11 | Kureha Chem Ind Co Ltd | 骨強度増強剤 |
| JPS63310828A (ja) * | 1987-06-10 | 1988-12-19 | Kureha Chem Ind Co Ltd | 経口骨折治癒促進剤 |
| JPH02231425A (ja) * | 1988-03-23 | 1990-09-13 | Teva Pharmaceut Ind Ltd | ヒトにおけるオステオポローシスの治療方法及び治療用組成物 |
| KR950000153A (ko) * | 1993-06-21 | 1995-01-03 | 아라끼 타다시 | 신성골이영양증(Renal Osteodystrophy)의 골질량감소 억제제 |
| US6263752B1 (en) | 1998-01-07 | 2001-07-24 | Nsk Ltd. | Transmission for automobiles and bearing therefor |
| US6283634B1 (en) | 1998-01-07 | 2001-09-04 | Nsk Ltd. | Transmission for automobiles and bearing therefor |
| US7674481B2 (en) * | 2003-04-09 | 2010-03-09 | Osmose, Inc. | Micronized wood preservative formulations |
| US8747909B2 (en) * | 2003-04-09 | 2014-06-10 | Osmose, Inc. | Micronized wood preservative formulations |
| US9079328B2 (en) | 2003-04-09 | 2015-07-14 | Koppers Performance Chemicals Inc. | Micronized wood preservative formulations |
| US8871277B2 (en) | 2003-06-17 | 2014-10-28 | Osmose, Inc. | Particulate wood preservative and method for producing the same |
| US8722198B2 (en) | 2004-05-17 | 2014-05-13 | Osmose, Inc. | Method of preserving wood by injecting particulate wood preservative slurry |
| US9314030B2 (en) | 2004-05-17 | 2016-04-19 | Koppers Performance Chemicals Inc. | Particulate wood preservative and method for producing same |
| US9775350B2 (en) | 2004-10-14 | 2017-10-03 | Koppers Performance Chemicals Inc. | Micronized wood preservative formulations in organic carriers |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3438821A1 (de) | 1985-05-02 |
| US4590184A (en) | 1986-05-20 |
| JPH0132208B2 (en, 2012) | 1989-06-29 |
| DE3438821C2 (en, 2012) | 1989-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6089422A (ja) | 抗骨粗鬆症剤 | |
| AU2007271900B2 (en) | Pharmaceutical and nutraceutical products comprising vitamin K2 | |
| EP1337263B1 (en) | A composition of rose hip and fish oil for alleviating joint pain and stiffness | |
| Avioli et al. | The nature of vitamin D resistance of patients with chronic renal disease | |
| AU625809B2 (en) | Novel calcium supplements | |
| DE3201865A1 (de) | Pharmazeutisches mittel und dessen verwendung fuer die behandlung der osteopathie | |
| JP2684587B2 (ja) | 腎性骨異栄養症における骨量減少抑制剤 | |
| Webb et al. | Chronic and subacute toxicology and pathology of methyl salicylate in dogs, rats, and rabbits | |
| Marghich et al. | Antidiarrheal Activity of Aqueous Extract of Artemisia campestris L. subsp. Glutinosa: doi. org/10.26538/tjnpr/v5i7. 14 | |
| Gimenez et al. | Prevention of phosphate-induced progression of uremia in rats by 3-phosphocitric acid | |
| Steendijk | Section II BASIC SCIENCE AND PATHOLOGY: Metabolic Bone Disease in Children. | |
| US4125621A (en) | Antiosteoporotic agents | |
| JPH0780773B2 (ja) | 新規ビタミンｄ▲下３▼誘導体を有効成分とする医薬 | |
| US5001118A (en) | Method for preventing senescence and increasing bone mass | |
| JP2876547B2 (ja) | 抗クル病剤 | |
| JP2023038290A (ja) | ロイシン誘導体、それを含む組成物及びその用途 | |
| ES2236487T3 (es) | Formulacion farmaceutica y su uso para preparar un medicamento para el tratamiento de enfermedades cardiovasculares. | |
| Fleming et al. | The influence of aging on intestinal absorption of vitamins A and D by the rat | |
| JP2543627B2 (ja) | 活性型ビタミンｄ含有治療剤 | |
| JPS61129130A (ja) | 抗尿毒症剤 | |
| JP2006516568A (ja) | 加齢関連性障害を処置するための組成物および方法 | |
| JPH0372206B2 (en, 2012) | ||
| RU2763761C1 (ru) | Гепатопротекторное гуминовое средство | |
| JPS58135812A (ja) | マグネシウム代謝調節剤 | |
| JPS61122214A (ja) | 抗リウマチ剤 |